Skip Navigation

Adalvo announces successful Pivotal BE program for Desogestrel + Ethinylestradiol

13 March 2023

We are pleased to announce that we have now completed our Pivotal BE program for Desogestrel+Ethinylestradiol film-coated tablets 0.15mg/0.03mg. This product has been developed in collaboration with one of our strategic partners.

Our product has been developed based on the reference brand Marvelon film-coated Tablets, which is used by women to prevent pregnancy and is a low dose contraceptive.

The INN with strength 0.15mg/0.03mg, sold approximately $152mn globally in 2021, according to IQVIA.

We offer an array of women’s health dossiers, and our intention is to assist our partners with the different challenges these mature products may entail.